Master Clinical Trial Agreements

 

Master Clinical Trial Agreements (MCTAs) provide agreed-upon terms and conditions establishing the basic relationship between the University and a Sponsor. Once a MCTA is in place, an addendum or study letter is typically generated for each new study to be done under the MCTA. The Addendum sets forth the items particular to a certain study such as budget/payment terms, schedule details, protocol name, and principal investigator. These Addenda are attached to the MCTA. This alleviates the need to negotiate the main terms of the agreement, as the majority of the terms are agreed upon and only the particular details need to be negotiated.

The use of Master Clinical Trial Agreements is a key tool in getting studies up and running as quickly and easily as possible. We now have MCTAs with over 40 commercial sponsors, and University Research Administration (URA) is continually working on revisions, renewals, and/or new agreements.

 

Below is a list of all the companies with whom we have current Master Clinical Trial Agreements. When dealing with the following sponsors, please inform them to use our MCTA.

AbbVie
Agios Pharma
Aimmune
Alpha Oncology
Alvine Pharma
Amgen
Aragon Pharma
Ardea Biosciences
Astellas
AstraZeneca
Academic Thoracic Oncology Medical Investigators Consortium (ATOMIC)
Biodexis
Bayer
Biogen
Boehringer
BMS
Celgene
Clovis Oncology
DuPont Pharma
EMD Serono
Genentech
Genzyme
Gilead
GSK
Guidant
Intermune
Janssen
Eli Lilly
Merck
Novartis
Novo Nordisk
PfizerĀ 
Pharmacyclics
Phillips Electronics
Regeneron
Scheering-Plough
Seattle Genetics
St. Jude's
Takeda
Taiho Pharma
TG Therapeutics
Titan Pharma
UCB Pharma
Veracyte